** Shares of Immunome Inc IMNM.O down 10% to $8.42 before the bell after overnight follow-on priced
** Bothell, Washington-based oncology specialist late Weds announced ~19.3 mln shares at $7.75 for $150 mln gross raise
** Deal size boosted from $125 mln, priced at 17.1% discount to last sale
** JP Morgan, TD Cowen, Leerink and Guggenheim jt bookrunners
** Co plans to use net offering proceeds to fund clinical/preclinical development of pipeline assets, and general purposes, per the SEC filing
** With ~62.42 mln shares outstanding, IMNM has ~$584 mln market cap, per LSEG data
** Through Weds close, stock down 12% YTD and down ~50% over the past 12 months
** Still, all 7 analysts covering IMNM are bullish, including 4 "strong buy" ratings with median PT of $31.50 - LSEG
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.